{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:49:19Z","timestamp":1779148159889,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd010557","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000}}],"reference-count":306,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010557.pub2","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T15:04:39Z","timestamp":1576595079000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Pharmacological interventions for treatment-resistant depression in adults"],"prefix":"10.1002","author":[{"given":"Philippa","family":"Davies","sequence":"first","affiliation":[{"name":"University of Bristol; Population Health Sciences, Bristol Medical School; Canynge Hall Bristol UK BS8 2PS"},{"name":"University Hospitals Bristol NHS Foundation Trust; NIHR ARC West; Bristol UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharea","family":"Ijaz","sequence":"additional","affiliation":[{"name":"University of Bristol; Population Health Sciences, Bristol Medical School; Canynge Hall Bristol UK BS8 2PS"},{"name":"University Hospitals Bristol NHS Foundation Trust; NIHR ARC West; Bristol UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine J","family":"Williams","sequence":"additional","affiliation":[{"name":"University of Bristol; School of Social and Community Medicine; 39 Whatley Road Bristol UK BS8 2PS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Kessler","sequence":"additional","affiliation":[{"name":"University of Bristol; Population Health Sciences, Bristol Medical School; Canynge Hall Bristol UK BS8 2PS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glyn","family":"Lewis","sequence":"additional","affiliation":[{"name":"UCL; UCL Division of Psychiatry; 67-73 Riding House St London UK W1W 7EJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Wiles","sequence":"additional","affiliation":[{"name":"University of Bristol; Population Health Sciences, Bristol Medical School; Canynge Hall Bristol UK BS8 2PS"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"10.1002\/14651858.CD010557.pub2-BIB0001|cit1","unstructured":"Appelberg BG Syvalahti E Muhonen T Koskinen T Naukkarinen H Mehtonen OP Patients with severe depression may benefit from buspirone augmentation of selective SSRIs 153rd Annual Meeting of the American Psychiatric Association, 2000 May 13-18; Chicago (IL) 2000 NR470"},{"issue":"6","key":"10.1002\/14651858.CD010557.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.4088\/JCP.v62n0608","article-title":"Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study","volume":"62","author":"Appelberg","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4088\/JCP.08m04629","article-title":"Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study","volume":"70","author":"Bauer","year":"2009","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0004|cit4","unstructured":"NCT00351910 A multi-centre, double-blind, randomised, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR TM ) in combination with an antidepressant in the treatment of patients with major depressive disorder with inadequate response to an antidepressant treatment clinicaltrials.gov\/show\/NCT00351910"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0005|cit5","unstructured":"Dunner D Amsterdam JD Shelton RC Loebel A Adjunctive ziprasidone for resistant depression: 8-week pilot study 45th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2005 June 6 - 9; Boca Raton (FL) 2005 123"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0006|cit6","unstructured":"Dunner DL Amsterdam JD Shelton RC Hassman HA Rosenthal M Romano SJ Adjunctive ziprasidone in treatment-resistant depression: a pilot study 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco (CA) 2003 NR238"},{"issue":"7","key":"10.1002\/14651858.CD010557.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.4088\/JCP.v68n0714","article-title":"Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study","volume":"68","author":"Dunner","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0008|cit8","first-page":"S99","article-title":"Adjunctive ziprasidone in treatment-resistant depression: randomized, double-blind, 8-week pilot study","volume":"29 Suppl 1","author":"Dunner","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0009|cit9","unstructured":"Romano SJ Amsterdam JD Shelton RC Hassman H Rosenthal MH Dunner DL Adjunctive ziprasidone in treatment-resistant depression: pilot study 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22 San Francisco (CA) 2003 170"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4088\/JCP.15m10070","article-title":"Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder","volume":"77","author":"Durgam","year":"2016","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010557.pub2-BIB0011|cit11","first-page":"S352","article-title":"Efficacy and safety of cariprazine as adjunctive therapy in major depressive disorder: a double-blind, placebo-controlled study","volume":"39","author":"Fava","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0012|cit12","unstructured":"El-Khalili N Joyce M Atkinson S Buynak R Adjunctive extended-release quetiapine fumarate (quetiapine XR) in patients with major depressive disorder and inadequate antidepressant response 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington (DC) 2008 129"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1017\/S1461145710000015","article-title":"Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study","volume":"13","author":"El-Khalili","year":"2010","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0014|cit14","unstructured":"NCT00326105 A multicenter, double-blind, randomized, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR TM ) in combination with an antidepressant in the treatment of patients with major depressive disorder with inadequate response to an antidepressant treatment (PEARL STUDY) clinicaltrials.gov\/show\/NCT00326105"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Ferreri M Lavergne F Berlin I Payan C Puech AJ Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone Acta Psychiatrica Scandinavica 2001 66 72","DOI":"10.1111\/j.1600-0447.2001.00148.x"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0016|cit16","unstructured":"ISRCTN06653773 Mirtazapine for treatment resistant depression isrctn.com\/ISRCTN06653773"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Kessler D Burns A Tallon D Lewis G MacNeill S Round J Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT Health Technology Assessment 2018 1 136","DOI":"10.3310\/hta22630"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Kessler DS MacNeill SJ Tallon D Lewis G Peters TJ Hollingwoth W Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR) BMJ 2018 k4218","DOI":"10.1136\/bmj.k4218"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13063-016-1199-2","article-title":"Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial","volume":"17","author":"Tallon","year":"2016","journal-title":"Trials"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0020|cit20","doi-asserted-by":"crossref","unstructured":"McIntyre A Gendron A McIntyre A Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study Depression & Anxiety 2007 487 94","DOI":"10.1002\/da.20275"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010557.pub2-BIB0021|cit21","first-page":"S172","article-title":"Ziprasidone vs. placebo augmentation of escitalopram for patients with vs. without anxious depression","volume":"40","author":"Ionescu","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD010557.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/YIC.0000000000000133","article-title":"Ziprasidone augmentation for anxious depression","volume":"31","author":"Ionescu","year":"2016","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010557.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4088\/JCP.16m10920","article-title":"Efficacy of ziprasidone augmentation of escitalopram for cognitive symptoms of major depressive disorder","volume":"79","author":"Iovieno","year":"2018","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010557.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4088\/JCP.15m10426","article-title":"Ziprasidone augmentation of escitalopram for major depressive disorder: cardiac, endocrine, metabolic, and motoric effects in a randomized, double-blind, placebo-controlled study","volume":"78","author":"Mischoulon","year":"2017","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0025|cit25","unstructured":"NCT00633399 Ziprasidone augmentation of SSRIs for patients with major depressive disorder (MDD) that do not sufficiently respond to treatment with SSRIs clinicaltrials.gov\/show\/NCT00633399"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010557.pub2-BIB0026|cit26","first-page":"S146","article-title":"Ziprasidone augmentation of escitalopram for major depressive disorder: Safety and tolerability","volume":"40","author":"Papakostas","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010557.pub2-BIB0027|cit27","first-page":"S344","article-title":"An 8-week, randomized, double-blind, placebo-controlled trial of adjunctive ziprasidone in patients with major depressive disorder receiving treatment with escitalopram","volume":"39","author":"Papakostas","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1176\/appi.ajp.2015.14101251","article-title":"Ziprasidone augmentation of escitalopram for major depressive disorder: efficacy results from a randomized, double-blind, placebo-controlled Study","volume":"172","author":"Papakostas","year":"2015","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0029|cit29","doi-asserted-by":"crossref","unstructured":"Shelton RC Tohen M Stahl S Jacobs T Gannon KS Tollefson GD The study of olanzapine plus fluoxetine in treatment-resistant major depressive disorder without psychotic features Schizophrenia Research 2000 193","DOI":"10.1016\/S0920-9964(00)90772-2"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1176\/appi.ajp.158.1.131","article-title":"A novel augmentation strategy for treating resistant major depression","volume":"158","author":"Shelton","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD010557.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0924-977X(99)80224-7","article-title":"Olanzapine plus fluoxetine: double-blind and open-label results in treatment-resistant major depressive disorder","volume":"9","author":"Tohen","year":"1999","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0032|cit32","first-page":"133","article-title":"The study of olanzapine plus fluoxetine in treatment-resistant major depressive disorder without psychotic features","volume":"Abstracts Volum","author":"Tollefson","year":"1999","journal-title":"XI World Congress of Psychiatry ; 1999 April 6-11; Hamburg (Germany)"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010557.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/S0924-977X(98)80241-1","article-title":"Efficacy of olanzapine, fluoxetine and combination therapy in treatment-resistant major depressive disorder without psychotic features","volume":"8","author":"Tollefson","year":"1998","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0034|cit34","unstructured":"Tollefson GD Shelton RC Tohen MF Stahl SM Jacobs L Gannon KS The study of olanzapine plus fluoxetine in treatment-resistant MDD without psychotic features 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington (DC) 1999 NR455"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010557.pub2-BIB0035|cit35","first-page":"141","article-title":"Treatment resistant major depression; a comparison of fluoxetine\/olanzapine combination therapy with venlafaxine","volume":"5","author":"Aarnell","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0036|cit36","unstructured":"Aarnell G Borjesson AM Eder DN Olausson B Hetta J Treatment resistant major depression XIIth World Congress of Psychiatry; 2002 August 24-29; Yokohama, Japan 2002"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/YIC.0b013e32836220df","article-title":"The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression","volume":"28","author":"Dording","year":"2013","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000332050","article-title":"A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study)","volume":"81","author":"Fava","year":"2012","journal-title":"Psychotherapy and Psychosomatics"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4088\/JCP.10m06541","article-title":"Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: randomized, double-blind, placebo-controlled, efficacy trial","volume":"73","author":"Mischoulon","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0040|cit40","unstructured":"NCT00683852 A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy (ADT) among outpatients with major depressive disorder who have responded inadequately to prior ADT clinicaltrials.gov\/show\/NCT00683852"},{"issue":"2","key":"10.1002\/14651858.CD010557.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/da.20080","article-title":"Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study","volume":"22","author":"Baca","year":"2005","journal-title":"Depression and Anxiety"},{"issue":"10","key":"10.1002\/14651858.CD010557.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.4088\/JCP.09m05355gre","article-title":"A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression","volume":"72","author":"Barbee","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0043|cit43","unstructured":"NCT00901407 Lamotrigine augmentation in resistant depression https:\/\/clinicaltrials.gov\/show\/NCT00901407"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Bares M Novak T Kopecek M Stopkova P Cermak J Kozeny J Antidepressant combinations and monotherapy in the treatment of resistant depression: a randomised, open-label study 24th Congress of the European College of Neuropsychopharmacology; 2011 September 3-7; Paris (France) 2011 S356","DOI":"10.1016\/S0924-977X(11)70568-5"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/13651501.2012.674533","article-title":"Antidepressant monotherapy compared with combinations of antidepressants in the treatment of resistant depressive patients: a randomized, open-label study","volume":"17","author":"Bares","year":"2013","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jad.2013.05.079","article-title":"Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder","volume":"151","author":"Bauer","year":"2013","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0047|cit47","unstructured":"Euctr2008-000908-91 A randomised, 6-week, multicentre, open-label, rater-blinded parallel group study comparing quetiapine extended release monotherapy and augmentation with Lithium augmentation in patients with treatment resistant depression - RUBY clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2008-000908-91"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0048|cit48","doi-asserted-by":"crossref","unstructured":"Franco MM Figueira ML Petrov P Rihmer Z Vavrusov L Dencker-Vansvik E Quetiapine XR monotherapy and quetiapine XR + ongoing antidepressant versus lithium + ongoing AD for stage II treatment-resistant major depressive disorder 23rd European College of Neuropsychopharmacology Congress; 2010 August 28-September 1; Amsterdam, Netherlands 2010 S347","DOI":"10.1016\/S0924-977X(10)70480-6"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0049|cit49","unstructured":"NCT00789854 Comparing quetiapine XR monotherapy and augmentation with lithium augmentation in TRD patients clinicaltrials.gov\/show\/NCT00789854"},{"issue":"1","key":"10.1002\/14651858.CD010557.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1017\/neu.2018.23","article-title":"A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder","volume":"31","author":"Bauer","year":"2018","journal-title":"Acta Neuropsychiatrica"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0051|cit51","first-page":"159","article-title":"Paroxetine vs. maprotiline: effects of dose escalation in non-responding depressed outpatients after 3 weeks of treatment","volume":"28","author":"Anghelescu","year":"1995","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1600-0447.1997.tb09634.x","article-title":"Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response","volume":"95","author":"Benkert","year":"1997","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-2007-979490","article-title":"A double-blind study comparing paroxetine and maprotiline in depressed outpatients","volume":"30","author":"Szegedi","year":"1997","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.1002\/14651858.CD010557.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4088\/JCP.v68n0604","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study","volume":"68","author":"Berman","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010557.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S1092852900020216","article-title":"Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants","volume":"14","author":"Berman","year":"2009","journal-title":"CNS Spectrums"},{"issue":"11","key":"10.1002\/14651858.CD010557.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.4088\/JCP.v65n1110","article-title":"Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients","volume":"65","author":"Birkenhager","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/11631890-000000000-00000","article-title":"Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine","volume":"32","author":"Bose","year":"2012","journal-title":"Clinical Drug Investigation"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.4088\/JCP.09m05723blu","article-title":"Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial","volume":"72","author":"Brecht","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-244X-8-73","article-title":"The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial","volume":"8","author":"Chaput","year":"2008","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0060|cit60","doi-asserted-by":"crossref","unstructured":"Chaput Y Magnan A Lebel MJ Adjunctive quetiapine administration to cognitive-behavior therapy 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York (NY) 2004 NR511","DOI":"10.1176\/pn.39.4.0001"},{"issue":"2","key":"10.1002\/14651858.CD010557.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/JCP.0000000000000663","article-title":"Comparison of the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder unresponsive to selective serotonin reuptake inhibitors: a randomized, prospective, open-label study","volume":"37","author":"Cheon","year":"2017","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0062|cit62","doi-asserted-by":"crossref","unstructured":"Koo BH Cheon EJ Lee KH Park YW Lee JH Lee SJ Effects of aripiprazole versus bupropion adjunctive to selective serotonin reuptake inhibitor on the specific symptoms of depression: a randomised prospective open-label multi-center study 29th European College of Neuropsychopharmacology Congress; 2016 September 17-20; Vienna, Austria 2017 S461","DOI":"10.1016\/S0924-977X(16)31455-9"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0063|cit63","doi-asserted-by":"crossref","unstructured":"Lee K Lee JB Park YW Lee JH Lee SJ Koo BH Comparison of aripiprazole augmentation versus bupropion combination for patient with major depressive disorder 27th European College of Neuropsychopharmacology Congress; 2014 October 18-21; Berlin, Germany 2014 S452 3","DOI":"10.1016\/S0924-977X(14)70724-2"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/1471-244X-13-212","article-title":"Effectiveness of lithium in subjects with treatment-resistant depression and suicide risk: a protocol for a randomised, independent, pragmatic, multicentre, parallel-group, superiority clinical trial","volume":"13","author":"Cipriani","year":"2013","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1186\/1756-0500-7-731","article-title":"Effectiveness of lithium in subjects with treatment-resistant depression and suicide risk: results and lessons of an underpowered randomised clinical trial","volume":"7","author":"Girlanda","year":"2014","journal-title":"BMC Research Notes"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0066|cit66","unstructured":"NCT00927550 Lithium and standard therapy in resistant depression clinicaltrials.gov\/show\/NCT00927550"},{"issue":"6","key":"10.1002\/14651858.CD010557.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/da.20130","article-title":"A randomized, double-blind comparison of olanzapine\/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression","volume":"23","author":"Corya","year":"2006","journal-title":"Depression and Anxiety"},{"issue":"2","key":"10.1002\/14651858.CD010557.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1185\/030079906X162809","article-title":"Quetiapine augmentation of treatment-resistant depression: a comparison with lithium","volume":"23","author":"Doree","year":"2007","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0069|cit69","unstructured":"Doree JP Tourjman SV Kunicki S Desrosiers J Vanier C Elie R Comparison of quetiapine versus lithium treatment of resistant depression 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York (NY) 2004 NR725"},{"issue":"4","key":"10.1002\/14651858.CD010557.pub2-BIB0070|cit70","first-page":"62","article-title":"Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial","volume":"48","author":"Earley","year":"2018","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0071|cit71","article-title":"A double-blind, placebo-controlled trial of lithium augmentation of antidepressants in treatment-resistant depression in elderly patients","author":"Edwards","year":"1998","journal-title":"National Research Register"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0072|cit72","unstructured":"Euctr2013-000719-26 A single centre, double blind, non-inferiority study to evaluate the antidepressant activity of Viotra TM compared with amitriptyline in the treatment of major depressive disorder (MDD) in patients who have an unsatisfactory response clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2013-000719-26"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0073|cit73","unstructured":"NCT02014363 Double blind, non-inferiority study to evaluate the antidepressant activity of ETS6103 compared with amitriptyline in the treatment of major depressive disorder (MDD) in patients who have an unsatisfactory response to selective serotonin re-uptake inhibitors (SSRIs) clinicaltrials.gov\/show\/NCT02014363"},{"issue":"4","key":"10.1002\/14651858.CD010557.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/JCP.0b013e3181e7784f","article-title":"Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population","volume":"30","author":"Fang","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/JCP.0b013e31822bb1d9","article-title":"A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression","volume":"31","author":"Fang","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD010557.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1176\/ajp.151.9.1372","article-title":"Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study","volume":"151","author":"Fava","year":"1994","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD010557.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4088\/JCP.v62n0603","article-title":"Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial","volume":"62","author":"Fava","year":"2001","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0078|cit78","unstructured":"Fava M Greist JH Preskorn SH Trivedi MH Zajecka JM Cohen M An open-label study with mirtazapine in depressed patients who are SSRI treatment failures 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington (DC) 1999"},{"issue":"4","key":"10.1002\/14651858.CD010557.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00004714-200208000-00008","article-title":"Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine","volume":"22","author":"Fava","year":"2002","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD010557.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/YIC.0000000000000235","article-title":"Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Fava","year":"2018","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0081|cit81","unstructured":"NCT00854100 A double-blind, placebo-controlled study of caripazine (RGH-188) as adjunctive therapy In major depressive disorder clinicaltrials.gov\/show\/NCT00854100"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.euroneuro.2014.04.004","article-title":"Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial","volume":"24","author":"Fornaro","year":"2014","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jad.2013.02.003","article-title":"Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study","volume":"149","author":"Franco-Chaves","year":"2013","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0084|cit84","unstructured":"NCT00086307 Combining a dopamine agonist and selective serotonin reuptake inhibitor for treatment of depression: a double-blind, randomized study clinicaltrials.gov\/show\/NCT00086307"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1745-6215-12-116","article-title":"Strategic use of new generation antidepressants for depression: SUN-D study protocol","volume":"12","author":"Furukawa","year":"2011","journal-title":"Trials"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s13063-015-0985-6","article-title":"Strategic use of new generation antidepressants for depression: SUN-D protocol update and statistical analysis plan","volume":"16","author":"Yonemoto","year":"2015","journal-title":"Trials"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1192\/bjp.109.458.54","article-title":"Trial of amitriptyline in chronic depression","volume":"109","author":"Garry","year":"1963","journal-title":"British Journal of Psychiatry"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD010557.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0924-977X(99)80131-X","article-title":"Buspiron and pindolol in augmentation therapy of treatment-resistant depression","volume":"9","author":"Gonul","year":"1999","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/YIC.0000000000000166","article-title":"Double-blind switch study of vilazodone in the treatment of major depressive disorder","volume":"32","author":"Grant","year":"2017","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jpsychires.2015.04.020","article-title":"Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: a 6-week, randomized, rater-blinded, prospective study","volume":"66-67","author":"Han","year":"2015","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0091|cit91","unstructured":"NCT01488266 Comparison of aripiprazole augmentation vs switching to different class of antidepressants for patients with MDD who are partially\/minimally responsive to current antidepressants: randomized, rater-blinded, prospective study clinicaltrials.gov\/show\/NCT01488266"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0092|cit92","unstructured":"Hides L Lubman D Wong L Carroll S Kay-Lambkin F Allen N Treating coexisting depression and alcohol\/other drug misuse in young people 29th Australian Association for Cognitive and Behaviour Therapy Annual Conference; 2006 October 18 - 23; Sydney, Australia 2006 50"},{"issue":"4","key":"10.1002\/14651858.CD010557.pub2-BIB0093|cit93","first-page":"7","article-title":"A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg\/d as adjunctive treatment of adults with major depressive disorder","volume":"79","author":"Hobart","year":"2018","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0094|cit94","doi-asserted-by":"crossref","unstructured":"Horikoshi SH Miura IM Yamamoto SY Abe OA Ito MI Watanabe KW Low and high dose aripiprazole augmentation in major depressive disorder: a randomised, open-label study 30th European College of Neuropsychopharmacology Congress; 2017 September 2-5; Paris, France 2017 S861","DOI":"10.1016\/S0924-977X(17)31545-6"},{"issue":"5","key":"10.1002\/14651858.CD010557.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archpsyc.1993.01820170065008","article-title":"A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression","volume":"50","author":"Joffe","year":"1993","journal-title":"Archives of General Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD010557.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1177\/070674370605101209","article-title":"Lithium and triiodothyronine augmentation of antidepressants","volume":"51","author":"Joffe","year":"2006","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jad.2013.07.035","article-title":"Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study)","volume":"151","author":"Kamijima","year":"2013","journal-title":"Journal of Affective Disorders"},{"issue":"8","key":"10.1002\/14651858.CD010557.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/pcn.12663","article-title":"Randomized, double-blind comparison of aripiprazole\/sertraline combination and placebo\/sertraline combination in patients with major depressive disorder","volume":"72","author":"Kamijima","year":"2018","journal-title":"Psychiatry and Clinical Neurosciences"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0099|cit99","unstructured":"Keitner G Ninan P Ryan C Garlow S Solomon D Nemeroff C A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, nonpsychotic major depression 46th Annual New Clinical Drug Evaluation Unit Meeting; 2006 June 12 - 15; Boca Raton (FL) 2006 142"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jpsychires.2008.05.003","article-title":"A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression","volume":"43","author":"Keitner","year":"2009","journal-title":"Journal of Psychiatric Research"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0101|cit101","first-page":"S175","article-title":"A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, nonpsychotic major depression","volume":"30 Suppl 1","author":"Keitner","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD010557.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"439","DOI":"10.4088\/JCP.v64n0414","article-title":"Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial","volume":"64","author":"Kennedy","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/archpsyc.1988.01800270071008","article-title":"Imipramine treatment for chronic depression","volume":"45","author":"Kocsis","year":"1988","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010557.pub2-BIB0104|cit104","first-page":"56","article-title":"Long-term follow-up of chronic depression treated with imipramine","volume":"52","author":"Kocsis","year":"1991","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1017\/S1092852913000813","article-title":"How to switch to agomelatine after an unsuccessful try with paroxetine or venlafaxine","volume":"20","author":"Lejoyeux","year":"2015","journal-title":"CNS Spectrums"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0106|cit106","doi-asserted-by":"crossref","unstructured":"Lejoyeux M Picarel-Blanchot F De Bodinat C How to switch to agomelatine after an initial treatment failure of paroxetine or venlafaxine? 26th European College of Neuropsychopharmacology Congress; 2013 October 5-10; Barcelona, Spain 2013 S341 2","DOI":"10.1016\/S0924-977X(13)70537-6"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/YIC.0b013e3282f424c2","article-title":"Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor","volume":"23","author":"Lenox-Smith","year":"2008","journal-title":"International Clinical Psychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD010557.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jagp.2016.04.015","article-title":"Impact of prior treatment on remission of late-life depression with venlafaxine and subsequent aripiprazole or placebo augmentation","volume":"24","author":"Hsu","year":"2016","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010557.pub2-BIB0109|cit109","first-page":"no pagination","article-title":"Clinical predictors of extrapyramidal symptoms associated with aripiprazole augmentation for the treatment of late-life depression in a randomized controlled trial","volume":"79","author":"Hsu","year":"2018","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010557.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/jamapsychiatry.2015.3447","article-title":"Predictors and moderators of remission with aripiprazole augmentation in treatment-resistant late-life depression: an analysis of the IRL-grey randomized clinical trial","volume":"73","author":"Kaneriya","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"10011","key":"10.1002\/14651858.CD010557.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(15)00308-6","article-title":"Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial","volume":"386","author":"Lenze","year":"2015","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0112|cit112","unstructured":"NCT00892047 Incomplete response in late life depression: getting to remission clinicaltrials.gov\/show\/NCT00892047"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpsychires.2016.07.005","article-title":"Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder","volume":"81","author":"Smagula","year":"2016","journal-title":"Journal of Psychiatric Research"},{"issue":"30","key":"10.1002\/14651858.CD010557.pub2-BIB0114|cit114","first-page":"4","article-title":"Venlafaxine extended release and lithium salt for major depressive disorder in nonresponders to selective serotonin reuptake inhibitors","volume":"10","author":"Li","year":"2006","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1176\/appi.neuropsych.12070171","article-title":"The combined treatment of venlafaxine and quetiapine for treatment-resistant depression: a clinical study","volume":"25","author":"Li","year":"2013","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010557.pub2-BIB0116|cit116","first-page":"236","article-title":"Mianserin augmentation, sertraline dose increase or extended duration of treatment in major depression insufficiently responding to 6 weeks of sertraline treatment","volume":"3","author":"Licht","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD010557.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00213-002-0999-0","article-title":"Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation","volume":"161","author":"Licht","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0118|cit118","unstructured":"Licht RW Qvitzav S Mianserin augmentation, sertraline dose increase or extended duration of treatment in major depression insufficiently responding to 6 weeks of sertraline treatment: a randomized, double-blind study 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 December 10-14; San Juan, Puerto Rico 2000 150"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0119|cit119","unstructured":"Licht RW Qvitzav S Mianserin augmentation, sertraline dose increase, or extended duration of treatment in patients with major depression nonresponding after six weeks of sertraline treatment: a randomized, double-blind study 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans (LA) 2001 NR369"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0120|cit120","unstructured":"Licht RW Qvitzav S Mianserin augmentation, sertraline dose increase, or extended duration of treatment in patients with major depression nonresponding after six weeks of sertraline treatment: a randomized, double-blind study 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia (PA) 2002"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0165-0327(96)00089-4","article-title":"Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression","volume":"41","author":"Maes","year":"1996","journal-title":"Journal of Affective Disorders"},{"issue":"2","key":"10.1002\/14651858.CD010557.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00004714-199904000-00014","article-title":"Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance","volume":"19","author":"Maes","year":"1999","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD010557.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/JCP.0b013e31816774f9","article-title":"The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study","volume":"28","author":"Marcus","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010557.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12888-017-1393-0","article-title":"Study protocol for a randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression (the LQD study)","volume":"17","author":"Marwood","year":"2017","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0125|cit125","unstructured":"NCT03004521 Lithium versus quetiapine in treatment resistant depression clinicaltrials.gov\/show\/NCT03004521"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0126|cit126","unstructured":"Mattingly G Ilivicky H Canale J Anderson R Quetiapine augmentation for treatment-resistant depression 46th Annual New Clinical Drug Evaluation Unit Meeting; 2006 June 12-15; Boca Raton (FL) 2006 154"},{"issue":"5","key":"10.1002\/14651858.CD010557.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3109\/08039489409081375","article-title":"Mianserin added to tricyclic antidepressants in depressed patients not responding to a tricyclic antidepressant alone: a randomized, placebo-controlled, double-blind study","volume":"48","author":"Medhus","year":"1994","journal-title":"Nordic Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0129|cit128","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jama.2017.8036","article-title":"Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial","volume":"318","author":"Mohamed","year":"2017","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0128|cit129","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.psychres.2015.08.005","article-title":"The VA augmentation and switching treatments for improving depression outcomes (Vast-D) study: rationale and design considerations","volume":"229","author":"Mohamed","year":"2015","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0130|cit130","unstructured":"NCT01421342 CSP #576 - VA augmentation and switching treatments for improving depression outcomes (VAST-D) clinicaltrials.gov\/show\/NCT01421342"},{"issue":"1","key":"10.1002\/14651858.CD010557.pub2-BIB0131|cit131","first-page":"e1","article-title":"Comparing cost-effectiveness of aripiprazole augmentation with other \"next-step\" depression treatment strategies: a randomized clinical trial","volume":"80","author":"Yoon","year":"2018","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jad.2016.07.023","article-title":"Characteristics of U.S. veteran patients with major depressive disorder who require \"next-step\" treatments: a VAST-D report","volume":"206","author":"Zisook","year":"2016","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0133|cit133","doi-asserted-by":"crossref","unstructured":"Haggstrom L Nielsen RZ Danchenko N Poulsen L A randomised, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI\/SNRI treatment 26th European College of Neuropsychopharmacology Congress; 2013 October 5-9; Barcelona, Spain 2013 S412","DOI":"10.1016\/S0924-977X(13)70652-7"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0134|cit134","doi-asserted-by":"crossref","unstructured":"Haggstrom L Nielsen RZ Dragheim M Randomized, double-blind, study of vortioxetine versus agomelatine in adults with MDD after inadequate response to SSRI or SNRI treatment 21st European Congress of Psychiatry; 2013 April 6-9; Nice, France 2013 3009","DOI":"10.1016\/S0924-9338(13)77519-9"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"470-82; Erratum","DOI":"10.1002\/hup.2424","article-title":"A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine","volume":"29","author":"Montgomery","year":"2014","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0136|cit136","unstructured":"NCT01488071 A randomised, double-blind, parallel-group, active-controlled, flexible dose study evaluating the effects of Lu AA21004 versus agomelatine in adult patients suffering from major depressive disorder with inadequate response to antidepressant treatment clinicaltrials.gov\/show\/NCT01488071"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0137|cit137","doi-asserted-by":"crossref","unstructured":"Papakostas G Dragheim M Nielsen RZ Efficacy and tolerability of vortioxetine is independent of previous treatment in MDD patients switched after an inadequate response 27th European College of Neuropsychopharmacology Congress; 2014 October 18-21; Berlin, Germany 2014 S466","DOI":"10.1016\/S0924-977X(14)70745-X"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"72-9","DOI":"10.1016\/j.jpsychires.2018.02.017","article-title":"Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response","volume":"101","author":"Papakostas","year":"2018","journal-title":"Journal of Psychiatric Research"},{"issue":"10","key":"10.1002\/14651858.CD010557.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"437","DOI":"10.4088\/JCP.v58n1005","article-title":"Pindolol augmentation of treatment-resistant depressed patients","volume":"58","author":"Moreno","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.pnpbp.2011.08.008","article-title":"Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression? A randomized open-label trial","volume":"35","author":"Nakajima","year":"2011","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0141|cit141","unstructured":"NCT00273624 Olanzapine augmentation therapy in treatment-resistant depression: a double-blind placebo-controlled trial clinicaltrials.gov\/show\/NCT00273624"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0142|cit142","unstructured":"NCT00296517 Clinical evaluation of 323U66 SR in patients with depression - placebo-controlled, double-blind, comparative study in patients with depression who did not respond sufficiently to selective serotonin re-uptake inhibitors clinicaltrials.gov\/show\/NCT00296517"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0143|cit143","unstructured":"NCT01052077 A phase 2, multicenter, randomized, double-blind, placebo-controlled study of the safety and efficacy of OPDC-34712 (1 to 3 mg\/Day) as adjunctive therapy in the treatment of adults with major depressive disorder STEP-D222 clinicaltrials.gov\/show\/NCT01052077"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0144|cit144","unstructured":"NCT02272517 An interventional, randomised, double-blind, parallel-group, active-comparator, flexible-dose study on the efficacy of vortioxetine versus escitalopram on cognitive dysfunction in patients with inadequate response to current antidepressant treatment of major depressive disorder clinicaltrials.gov\/show\/NCT02272517"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0145|cit145","unstructured":"NCT02960763 Optimizing outcomes of treatment-resistant depression in older adults (OPTIMUM) clinicaltrials.gov\/show\/NCT02960763"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0146|cit146","unstructured":"NCT02977299 Comparative effectiveness research trial for antidepressant incomplete and non-responders with TRD (ASCERTAINTRD) clinicaltrials.gov\/show\/NCT02977299"},{"issue":"1","key":"10.1002\/14651858.CD010557.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/00004714-200302000-00013","article-title":"Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants","volume":"23","author":"Nierenberg","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0165-0327(93)90104-R","article-title":"Monoamine oxidase inhibitors in resistant major depression: a double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants","volume":"28","author":"Nolen","year":"1993","journal-title":"Journal of Affective Disorders"},{"issue":"1","key":"10.1002\/14651858.CD010557.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4088\/JCP.v69n0113","article-title":"Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques","volume":"69","author":"Perahia","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jpsychires.2008.07.001","article-title":"Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression","volume":"43","author":"Perahia","year":"2009","journal-title":"Journal of Psychiatric Research"},{"issue":"4","key":"10.1002\/14651858.CD010557.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/archpsyc.56.4.375","article-title":"A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors","volume":"56","author":"Perez","year":"1999","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0152|cit152","doi-asserted-by":"crossref","unstructured":"Petrescu B Vasile D Vasiliu O Tudor C Mangalagiu A Ungureanu D SSRI dose escalation versus duloxetine in treatment of major depressive disorder not responding to initial SSRI 27th European College of Neuropsychopharmacology Congress; 2014 October 18-21; Berlin, Germany 2014 S455 6","DOI":"10.1016\/S0924-977X(14)70729-1"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0155|cit153","first-page":"55","article-title":"The concept of resistant depression and therapeutic strategies, particularly with venlafaxine","volume":"25 Spec No 2","author":"Poirier","year":"1999","journal-title":"Encephale"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0156|cit154","doi-asserted-by":"crossref","unstructured":"Poirier MF Venlafaxine versus paroxetine in the treatment of resistant depression Sixth World Congress of Biological Psychiatry; 1997 June 22-27; Nice, France 1997","DOI":"10.1016\/S0006-3223(97)87915-2"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0153|cit155","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1192\/bjp.175.1.12","article-title":"Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison","volume":"174","author":"Poirier","year":"1999","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0154|cit156","unstructured":"Poirier MF Boyer P Venlafaxine versus paroxetine for treatment resistant depression XXIst Collegium Internationale Neuro Psychopharmacologicum; 1998 July 12-16; Glasgow, Scotland 1998"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0157|cit157","doi-asserted-by":"crossref","unstructured":"Schaeffer P Poirier FM Boyer P Double-blind trial of venlafaxine and paroxetine for treatment-resistant depression 11th European College of Neuropsychopharmacology Congress; 1998 October 31- November 4; Paris, France 1998","DOI":"10.1016\/S0924-977X(98)80190-9"},{"issue":"9","key":"10.1002\/14651858.CD010557.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7326\/0003-4819-147-9-200711060-00003","article-title":"Risperidone for treatment-refractory major depressive disorder: a randomized trial","volume":"147","author":"Mahmoud","year":"2007","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0159|cit159","first-page":"S159","article-title":"Augmentation with risperidone in chronic resistant depression: a double-blind placebo-controlled maintenance trial","volume":"29 Suppl 1","author":"Nemeroff","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0160|cit160","unstructured":"Rapaport MH Canuso CM Loescher A Lasser R Gharabawi G Preliminary results from the ARISe-RD (risperidone augmentation in resistant depression) trial 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22, San Francisco (CA) 2003 NR179"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0161|cit161","unstructured":"Rapaport MH Canuso CM Rouillon F Leblanc J Young AH Loescher A Results from the augmentation with risperidone in resistant depression trial 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York (NY) 2004 NR799"},{"issue":"11","key":"10.1002\/14651858.CD010557.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/sj.npp.1301113","article-title":"Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation","volume":"31","author":"Rapaport","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0163|cit163","unstructured":"NCT01282632 Risperidone vs. olanzapine as add-on treatment in treatment resistant depression clinicaltrials.gov\/show\/NCT01282632"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0165|cit164","unstructured":"Ravindran L Lam R Chaput Y Enns M Levitt A Impact of low vs. high dose olanzapine or risperidone on outcome and side effects in non-psychotic treatment resistant depression 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12 - 15; Boca Raton (FL) 2006 251"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0164|cit165","unstructured":"Ravindran L Lam R Chaput Y Enns M Levitt A Impact of low vs. high dose olanzapine or risperidone on outcome and side effects in non-psychotic treatment resistant depression (TRD) World Psychiatric Association International Congress; 2006 July 12 - 16; Istanbul, Turkey 2006 325"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/YIC.0000000000000075","article-title":"Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial","volume":"30","author":"Clayton","year":"2015","journal-title":"International Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD010557.pub2-BIB0167|cit167","first-page":"no pagination","article-title":"An 8-week randomized, double-blind trial comparing efficacy, safety, and tolerability of 3 vilazodone dose-initiation strategies following switch from SSRIS and SNRIs in major depressive disorder","volume":"17","author":"Rele","year":"2015","journal-title":"Primary Care Companion to CNS Disorders"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0168|cit168","unstructured":"Romera I Gilaberte I Perez V Menchon JM Papen R Schacht A Early antidepressant switch in MDD with pain symptoms: functional improvement 11th International Forum on Mood and Anxiety Disorders; 2011 November 9-11; Budapest, Hungary 2011"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jad.2012.05.024","article-title":"Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study","volume":"143","author":"Romera","year":"2012","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JCP.0b013e31825d9958","article-title":"Early switch strategy in patients with major depression disorder: a double-blind, randomized study","volume":"32","author":"Romera","year":"2012","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0171|cit171","first-page":"34","article-title":"Early vs. delayed switch to duloxetine in patients with major depressive disorder not exhibiting early improvement with escitalopram: double-blind randomized study","volume":"14","author":"Romera","year":"2010","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psyneuen.2015.04.027","article-title":"Fatty acid metabolism and its longitudinal relationship with the hypothalamic-pituitary-adrenal axis in major depression: associations with prospective antidepressant response","volume":"59","author":"Mocking","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0173|cit173","doi-asserted-by":"crossref","unstructured":"Mocking RJT Verburg HF Westerink AM Assies J Vaz FM Koeter MWJ Longitudinal interplay between paroxetine response, cortisol and fatty acid metabolism in major depressive disorder abstract 27th European College of Neuropsychopharmacology Congress; 2014 October 18-21; Berlin, Germany 2014 S396 7","DOI":"10.1016\/S0924-977X(14)70632-7"},{"issue":"4","key":"10.1002\/14651858.CD010557.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/npp.2008.148","article-title":"Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy","volume":"34","author":"Ruhe","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4088\/JCP.10m06584","article-title":"Successful pharmacologic treatment of major depressive disorder attenuates amygdala activation to negative facial expressions: a functional magnetic resonance imaging study","volume":"73","author":"Ruhe","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.psyneuen.2014.10.024","article-title":"Longitudinal effects of the SSRI paroxetine on salivary cortisol in major depressive disorder","volume":"52","author":"Ruhe","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0177|cit177","doi-asserted-by":"crossref","unstructured":"Ruhe HG Van Rooijen G Veltman DJ Schene AH Twelve weeks of paroxetine treatment improves prefrontal brain activity. An fMRI study using the Tower of London 23rd European College of Neuropsychopharmacology (ECNP) Congress; 2010 August 28-September 01; Amsterdam, The Netherlands 2010 S380","DOI":"10.1016\/S0924-977X(10)70537-X"},{"issue":"1","key":"10.1002\/14651858.CD010557.pub2-BIB0178|cit178","first-page":"33","article-title":"Improvement in subjective work performance after treatment of chronic depression: some preliminary results","volume":"32","author":"Finkelstein","year":"1996","journal-title":"Psychopharmacolgy Bulletin"},{"issue":"11","key":"10.1002\/14651858.CD010557.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"608","DOI":"10.4088\/JCP.v59n1108","article-title":"The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine","volume":"59","author":"Miller","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD010557.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4088\/JCP.v59n1106","article-title":"The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies","volume":"59","author":"Rush","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD010557.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4088\/JCP.v64n0510","article-title":"Chronic depression and comorbid personality disorders: response to sertraline versus imipramine","volume":"64","author":"Russell","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0182|cit182","first-page":"612","article-title":"Response to antidepressant treatment in chronically depressed patients with comorbid personality disorder","volume":"31","author":"Russell","year":"1995","journal-title":"Psychopharmacology Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/archpsyc.59.3.233","article-title":"Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression","volume":"59","author":"Thase","year":"2002","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000026610","article-title":"Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression","volume":"40","author":"Rybakowski","year":"1999","journal-title":"Neuropsychobiology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0185|cit185","unstructured":"Suwalska A Rybakowski J Potentiation of antidepressants with lithium or carbamazepine 9th European College of Neuropsychopharmacology Congress; 1996 September 21-26; Amsterdam, The Netherlands 1996"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0186|cit186","unstructured":"Suwalska A Rybakowski J Potentiation of antidepressants with lithium or carbamazepine: factors associated with therapeutic efficacy 11th European College of Neuropsychopharmacology Congress; 1998 October 31-November 4: Paris, France 1998"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0187|cit187","unstructured":"NCT00652171 Efficacy and safety of antidepressant augmentation with lamotrigine clinicaltrials.gov\/show\/NCT00652171"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4088\/PCC.v10n0302","article-title":"Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study","volume":"10","author":"Santos","year":"2008","journal-title":"Primary Care Companion to the Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/YIC.0b013e328014823d","article-title":"Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study","volume":"22","author":"Schindler","year":"2007","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010557.pub2-BIB0190|cit190","first-page":"8","article-title":"What constitutes an adequate antidepressant trial for fluoxetine?","volume":"51","author":"Schweizer","year":"1990","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0191|cit191","unstructured":"Rickels K DiMartinis N Rynn MA Schweizer EE Therapeutic equivalence of 50 mg and 150 mg sertraline in outpatient major depression: results from a clinical trial 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington (DC) 1999"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0192|cit192","unstructured":"Rickels K Schweizer E Rynn M DiMartinis N Sertraline 50 mg is as effective as 150 mg in MDD XI World Congress of Psychiatry; 1999 August 6-11; Hamburg, Germany 1999 128"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00004850-200105000-00002","article-title":"The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial","volume":"16","author":"Schweizer","year":"2001","journal-title":"International Clinical Psychopharmacology."},{"key":"10.1002\/14651858.CD010557.pub2-BIB0194|cit194","unstructured":"NCT00179244 Risperidone vs. bupropion ER augmentation of SSRIs in treatment-resistant depression clinicaltrials.gov\/show\/NCT00179244"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0195|cit195","first-page":"S238","article-title":"Risperidone vs. bupropion combined with SSRIs in treatment resistant unipolar major depression","volume":"30 Suppl 1","author":"Shelton","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0197|cit196","unstructured":"Shelton RC Atypical antipsychotics: treatment of depression 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington (DC) 1999"},{"issue":"10","key":"10.1002\/14651858.CD010557.pub2-BIB0196|cit197","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4088\/JCP.v66n1012","article-title":"Olanzapine\/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance","volume":"66","author":"Shelton","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/j.1552-4604.1981.tb01780.x","article-title":"Comparison of molindone and tranylcypromine in the treatment of refractory depression","volume":"21","author":"Small","year":"1981","journal-title":"Journal of Clinical Pharmacology"},{"issue":"52","key":"10.1002\/14651858.CD010557.pub2-BIB0199|cit199","first-page":"10486","article-title":"Venlafaxine combined with low-dose risperidone for treatment-resistant depression","volume":"11","author":"Song","year":"2007","journal-title":"Journal of Clinical Rehabilitative Tissue Engineering Research"},{"issue":"4","key":"10.1002\/14651858.CD010557.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00004714-199608000-00006","article-title":"A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation","volume":"16","author":"Baumann","year":"1996","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0201|cit201","first-page":"213","article-title":"Treatment of resistant depression with the citalopram-lithium combination: methodology of a double-blind multicenter study and preliminary results","volume":"17","author":"Souche","year":"1991","journal-title":"Encephale"},{"issue":"6","key":"10.1002\/14651858.CD010557.pub2-BIB0202|cit202","first-page":"465","article-title":"Treatment of resistant depression by association citalopram-lithium; methodology of a multicenter double-blind study, and preliminary results","volume":"16","author":"Souche","year":"1990","journal-title":"Encephale"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0203|cit203","unstructured":"ACTRN12610000564055 Patterns of treatment resistance and switching strategies in unipolar affective disorder www.anzctr.org.au\/ACTRN12610000564055.aspx"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3109\/15622975.2011.590225","article-title":"Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study","volume":"12","author":"Souery","year":"2011","journal-title":"World Journal of Biological Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0205|cit205","first-page":"13","article-title":"Advances on the treatment of resistant depression","volume":"14","author":"Souery","year":"2010","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1600-0447.2011.01791.x","article-title":"Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D TRIAL","volume":"125","author":"Bech","year":"2012","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"7","key":"10.1002\/14651858.CD010557.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1176\/ajp.2006.163.7.1161","article-title":"A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report","volume":"163","author":"Fava","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/JCP.0b013e31823f705d","article-title":"Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D","volume":"32","author":"Gaynes","year":"2012","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.genhosppsych.2011.10.001","article-title":"Risk of adverse events in treatment-resistant depression: propensity-score-matched comparison of antidepressant augment and switch strategies","volume":"34","author":"Hansen","year":"2012","journal-title":"General Hospital Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD010557.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1176\/ajp.2006.163.9.1531","article-title":"Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report","volume":"163","author":"McGrath","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD010557.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1176\/ajp.2006.163.9.1519","article-title":"A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report","volume":"163","author":"Nierenberg","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010557.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0197-2456(03)00112-0","article-title":"Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design","volume":"25","author":"Rush","year":"2004","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0213|cit213","unstructured":"Rush AJ Trivedi M Wisniewski SR Fava M An update on the STAR*D trial 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta (GA) 2005 9C"},{"issue":"12","key":"10.1002\/14651858.CD010557.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMoa052963","article-title":"Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression","volume":"354","author":"Rush","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010557.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1176\/ajp.2007.164.5.739","article-title":"Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report","volume":"164","author":"Thase","year":"2007","journal-title":"American Journal of Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD010557.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa052964","article-title":"Medication augmentation after the failure of SSRIs for depression","volume":"354","author":"Trivedi","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0217|cit217","first-page":"35","article-title":"Double-blind trial of lithium carbonate in tricyclic resistant depression","volume-title":"Birch NJ (ed). Lithium: Inorganic Pharmacology and Psychiatric Use","author":"Stein","year":"1988"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1192\/bjp.162.5.634","article-title":"Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses","volume":"162","author":"Stein","year":"1993","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010557.pub2-BIB0219|cit219","first-page":"221","article-title":"Comparative study of citalopram combined with buspirone for treatment of refractory depression","volume":"14","author":"Sun","year":"2004","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"8","key":"10.1002\/14651858.CD010557.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/archpsyc.1994.03950080019003","article-title":"High-dose selegiline in treatment-resistant older depressive patients","volume":"51","author":"Sunderland","year":"1994","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD010557.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/(SICI)1099-1077(199709\/10)12:5<509::AID-HUP915>3.0.CO;2-1","article-title":"Moclobemide and amitriptyline alone or in combination in therapy resistant depression","volume":"12","author":"Tanghe","year":"1997","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0222|cit222","unstructured":"Thase ME Kremer C Rodrigues H Mirtazapine versus sertraline after SSRI non-response 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 December 10-14; San Juan, Puerto Rico 2000 260"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0223|cit223","unstructured":"Thase ME Kremer C Rodrigues H Mirtazapine versus sertraline after SSRI nonresponse 52nd Institute on Psychiatric Services; 2000 October 25-29th; Philadelphia, PA 2000"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.jcp.0000219922.19305.08","article-title":"Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies","volume":"26","author":"Thase","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"878","DOI":"10.4088\/JCP.10m06744","article-title":"Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: a candidate gene analysis","volume":"73","author":"Houston","year":"2012","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0226|cit226","unstructured":"NCT00035321 The study of olanzapine plus fluoxetine in combination for treatment-resistant depression without psychotic features clinicaltrials.gov\/ct2\/show\/NCT00035321"},{"issue":"2","key":"10.1002\/14651858.CD010557.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4088\/JCP.v68n0207","article-title":"A randomized, double-blind comparison of olanzapine\/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder","volume":"68","author":"Thase","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0228|cit228","unstructured":"NCT00797966 Study of the safety and efficacy of OPC-34712 as adjunctive therapy in the treatment of patients with major depressive disorder clinicaltrials.gov\/show\/NCT00797966"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0229|cit229","unstructured":"Thase M Fava M Hobart M Skuban A Zhang P McQuade RD Efficacy of adjunctive OPC-34712 across multiple outcome measures in major depressive disorder: phase II, randomized, placebo-controlled study 50th Annual Meeting of the American College of Neuropsychopharmacology; 2011 December 4-8; Waikoloa (HI) 2011 S302 4"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0230|cit230","unstructured":"NCT01360645 A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of the safety and efficacy of fixed dose OPC-34712 as adjunctive therapy in the treatment of adults with major depressive disorder, the Pyxis trial clinicaltrials.gov\/show\/NCT01360645"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4088\/JCP.14m09688","article-title":"Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants","volume":"76","author":"Thase","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0232|cit232","unstructured":"NCT01360632 A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of the safety and efficacy of two fixed doses of OPDC-34712 as adjunctive therapy in the treatment of adults with major depressive disorder, the Polaris trial clinicaltrials.gov\/show\/NCT01360632"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.4088\/JCP.14m09689","article-title":"Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study","volume":"76","author":"Thase","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010557.pub2-BIB0234|cit234","first-page":"69","article-title":"Comparative study of citalopram combined with amitriptyline for treatment of refractory depression","volume":"11","author":"Yang","year":"2005","journal-title":"International Medicine and Health Guidance News"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.pnpbp.2012.07.008","article-title":"Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder","volume":"39","author":"Yoshimura","year":"2012","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0236|cit236","unstructured":"Yoshimura R Kishi T Hori H Ikenouchi-Sugita A Umene-Nakano W Katsuki A Comparison the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder 28th CINP World Congress of Neuropsychopharmacology; 2012 June 3-7; Stockholm, Sweden 2012 199"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/2045125313514767","article-title":"Comparison of lithium, aripiprazole and olanzapine as augmentation to paroxetine for inpatients with major depressive disorder","volume":"4","author":"Yoshimura","year":"2014","journal-title":"Therapeutic Advances in Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010557.pub2-BIB0238|cit238","first-page":"26","article-title":"A controlled trial of venlafaxine and paroxetine in treatment-refractory depression","volume":"13","author":"Zhao","year":"2003","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010557.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00004714-198804000-00007","article-title":"Adjunct low-dose lithium carbonate in treatment-resistant depression: a placebo-controlled study","volume":"8","author":"Zusky","year":"1988","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD010557.pub2-BIB0240|cit240","first-page":"129","article-title":"Controlled study of venlafaxine combined with quetiapine in refractory depression","volume":"11","author":"Cao","year":"2005","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0241|cit241","article-title":"Double blind randomised controlled trial comparing moclobemide and phenelzine in treatment resistant depression","author":"Clunie","year":"2001","journal-title":"National Research Register"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0242|cit242","unstructured":"Euctr-002130-11-Es Therapeutic strategies in major depressive disorder resistant to treatment with SSRIs. Pragmatic, parallel group, randomised trial with blinded evaluation clinicaltrialsregister.eu\/ctr-search\/trial\/2007-002130-11\/ES"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1742-7843.2011.00788.x","article-title":"Bupropion as an augmenting agent in patients of depression with partial response","volume":"110","author":"Gulrez","year":"2012","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"issue":"2","key":"10.1002\/14651858.CD010557.pub2-BIB0244|cit244","first-page":"354","article-title":"The efficacy of quetiapine XR as an adjunctive therapy to duloxetine in depressed patients with inadequate response to monotherapy","volume":"66","author":"Moica","year":"2018","journal-title":"Farmacia"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0245|cit245","first-page":"355","article-title":"A study of switching to mirtazapine for treatment-resistant depression","volume":"15","author":"Zhu","year":"2003","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010557.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/0269881107088441","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines","volume":"22","author":"Anderson","year":"2008","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","article-title":"A review of the pharmacological and clinical profile of mirtazapine","volume":"7","author":"Anttila","year":"2001","journal-title":"CNS Drug Reviews"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0248|cit248","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890423349","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, Text Revision (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0249|cit249","unstructured":"American Psychiatric Association Practice guideline for the treatment of patients with major depressive disorder psychiatryonline.org\/guidelines.aspx"},{"issue":"5","key":"10.1002\/14651858.CD010557.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00004714-199910000-00006","article-title":"Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies","volume":"19","author":"Bauer","year":"1999","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0252|cit252","volume-title":"Beck Depression Inventory: Manual","author":"Beck","year":"1996"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1600-0447.2009.01458.x","article-title":"No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy","volume":"121","author":"Bschor","year":"2010","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"15","key":"10.1002\/14651858.CD010557.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1017\/S0033291715001270","article-title":"Minimal clinically important difference on the Beck Depression Inventory-II according to the patient's perspective","volume":"45","author":"Button","year":"2015","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2710.2007.00846.x","article-title":"Augmentation strategies for treatment-resistant depression: a literature review","volume":"32","author":"Carvalho","year":"2007","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD010557.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/YCO.0b013e32831be9ef","article-title":"Augmentation strategies for treatment-resistant depression","volume":"22","author":"Carvalho","year":"2008","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0257|cit257","volume-title":"Statistical Power Analysis in the Behavioural Sciences","author":"Cohen","year":"1988"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1176\/appi.ajp.2011.10081165","article-title":"A systematic review of treatments for refractory depression in older people","volume":"168","author":"Cooper","year":"2011","journal-title":"American Journal of Psychiatry"},{"issue":"54","key":"10.1002\/14651858.CD010557.pub2-BIB0259|cit259","first-page":"1","article-title":"Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation","volume":"17","author":"Edwards","year":"2013","journal-title":"Health Technology Assessment (Winchester, England)"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-3223(03)00231-2","article-title":"Diagnosis and definition of treatment-resistant depression","volume":"53","author":"Fava","year":"2005","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archpsyc.1972.01750190059011","article-title":"Diagnostic criteria for use in psychiatric research","volume":"26","author":"Feighner","year":"1972","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010557.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4088\/JCP.08m04309","article-title":"A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method","volume":"70","author":"Fekadu","year":"2009","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1017\/S0033291712001511","article-title":"Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature","volume":"43","author":"Ferrari","year":"2013","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0265|cit265","first-page":"47","article-title":"Combined psychotherapy and pharmacotherapy for the treatment of major depressive disorder","volume":"11","author":"Friedman","year":"2004","journal-title":"Clinical Psychology: Science and Practice"},{"issue":"5","key":"10.1002\/14651858.CD010557.pub2-BIB0266|cit266","first-page":"370","article-title":"Cost burden of treatment resistance in patients with depression","volume":"16","author":"Gibson","year":"2010","journal-title":"American Journal of Managed Care"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0268|cit268","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0269|cit269","unstructured":"Higgins JPT Altman DG Cochrane Statistical Methods Group and the Cochrane Bias Methods Group Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"5","key":"10.1002\/14651858.CD010557.pub2-BIB0270|cit270","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010558.pub2","article-title":"Psychological therapies for treatment-resistant depression in adults","author":"Ijaz","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-publhealth-031912-114409","article-title":"The epidemiology of depression across cultures","volume":"34","author":"Kessler","year":"2013","journal-title":"Annual Review of Public Health"},{"issue":"Supplementum","key":"10.1002\/14651858.CD010557.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"3","key":"10.1002\/14651858.CD010557.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/hup.2465","article-title":"Is pindolol augmentation effective in depressed patients resistant to selective serotonin reuptake inhibitors? A systematic review and meta-analysis","volume":"30","author":"Liu","year":"2015","journal-title":"Human Psychopharmacology"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/archpsyc.1962.01720060019002","article-title":"Clinician's judgments of mental health","volume":"7","author":"Luborsky","year":"1962","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010557.pub2-BIB0275|cit275","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010557.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40801-017-0126-5","article-title":"Estimating prevalence and healthcare utilization for treatment-resistant depression in Japan: a retrospective claims database study","volume":"5","author":"Mahlich","year":"2018","journal-title":"Drugs - Real World Outcomes"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0277|cit277","unstructured":"Mathers CD Loncar D Updated Projections of Global Mortality and Burden of Disease, 2002-2030: Data Sources, Methods and Results (Working Paper) www.who.int\/healthinfo\/statistics\/bod_projections2030_paper.pdf"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"458","DOI":"10.5694\/j.1326-5377.2000.tb139294.x","article-title":"Recent trends in the use of antidepressant drugs in Australia","volume":"173","author":"McManus","year":"2000","journal-title":"Medical Journal of Australia"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/pubmed\/23.4.262","article-title":"Secular trends in antidepressant prescribing in the UK, 1975-1998","volume":"23","author":"Middleton","year":"2001","journal-title":"Journal of Public Health Medicine"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0281|cit281","unstructured":"NHS Digital Prescriptions dispensed in the community. England 2004-14 digital.nhs.uk\/catalogue\/PUB17644"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0282|cit282","unstructured":"NHS Information Centre Prescription cost analysis England 2010 www.hscic.gov.uk\/pubs\/prescostanalysis2010"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0283|cit283","unstructured":"National Institute for Health and Clinical Excellence Depression: the treatment and management of depression in adults. National Clinical Practice Guideline 23 www.nice.org.uk\/CG23"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0284|cit284","unstructured":"National Institute for Health and Clinical Excellence Depression: the treatment and management of depression in adults (update). National Clinical Practice Guideline 90 www.nice.org.uk\/CG90"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.psc.2007.01.001","article-title":"A critical overview of the pharmacologic management of treatment-resistant depression","volume":"30","author":"Nierenberg","year":"2007","journal-title":"Psychiatric Clinics of North America"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/archpsyc.61.7.714","article-title":"Combined pharmacotherapy and psychological treatment for depression","volume":"61","author":"Pampallona","year":"2004","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.biopsych.2007.08.010","article-title":"Treatment of SSRI-resistant depression: a meta-analysis comparing within-versus across-class switches","volume":"63","author":"Papakostas","year":"2008","journal-title":"Biological Psychiatry"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD010557.pub2-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4088\/JCP.8133su1c.03","article-title":"Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder","volume":"70","author":"Papakostas","year":"2009","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jama.279.7.526","article-title":"Prescribing trends in psychotropic medications","volume":"279","author":"Pincus","year":"1998","journal-title":"JAMA"},{"issue":"12","key":"10.1002\/14651858.CD010557.pub2-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.4088\/JCP.v67n1203","article-title":"Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review","volume":"67","author":"Ruhe","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1192\/bjp.bp.105.018325","article-title":"Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review","volume":"189","author":"Ruhe","year":"2006","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1600-0447.2007.01130.x","article-title":"Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder","volume":"117","author":"Shelton","year":"2008","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"6","key":"10.1002\/14651858.CD010557.pub2-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/archpsyc.1978.01770300115013","article-title":"Research diagnostic criteria: rationale and reliability","volume":"35","author":"Spitzer","year":"1978","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1192\/bjp.181.4.284","article-title":"Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression. Systematic review","volume":"181","author":"Stimpson","year":"2002","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0295|cit295","first-page":"23","article-title":"When at first you don't succeed: sequential strategies for antidepressant nonresponders","volume":"58 Suppl 13","author":"Thase","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"issue":"617","key":"10.1002\/14651858.CD010557.pub2-BIB0296|cit296","doi-asserted-by":"crossref","first-page":"e852","DOI":"10.3399\/bjgp13X675430","article-title":"Prevalence of treatment-resistant depression in primary care: cross-sectional data","volume":"63","author":"Thomas","year":"2013","journal-title":"British Journal of General Practice"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010557.pub2-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/mpr.139","article-title":"The economic burden of depression and the cost-effectiveness of treatment","volume":"12","author":"Wang","year":"2003","journal-title":"International Journal of Methods in Psychiatric Research"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0299|cit299","volume-title":"SF-36 Health Survey: Manual and Interpretation Guide","author":"Ware","year":"1993"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0300|cit300","volume-title":"International Statistical Classification of Diseases and Related Health Problems","author":"World Health Organization","year":"1992"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0277-9536(98)00009-4","article-title":"The World Health Organisation Quality of Life Assessment (WHOQOL): development and general psychometric properties","volume":"46","author":"WHOQOL Group","year":"1998","journal-title":"Social Science and Medicine"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0302|cit302","volume-title":"Measuring Mental Health Outcomes: a Perspective from the Royal College of Psychiatrists. Outcomes into Clinical Practice","author":"Wing","year":"1994"},{"key":"10.1002\/14651858.CD010557.pub2-BIB0303|cit303","first-page":"69","article-title":"Symposium on therapy resistant depression","volume":"7","author":"World Psychiatric Association","year":"1974","journal-title":"Pharmacopsychiatry"},{"issue":"11","key":"10.1002\/14651858.CD010557.pub2-BIB0304|cit304","doi-asserted-by":"publisher","first-page":"pyv060","DOI":"10.1093\/ijnp\/pyv060","article-title":"Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis","volume":"18","author":"Zhou","year":"2015","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD010557.pub2-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.4088\/JCP.14r09204","article-title":"Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis","volume":"76","author":"Zhou","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD010557.pub2-BIB0306|cit306","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010557","article-title":"Pharmacological interventions for treatment-resistant depression in adults","author":"Williams","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD010557.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T18:21:09Z","timestamp":1665253269000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD010557.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Common Mental Disorders Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":306,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010557.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]}}}